EP0709099A3
(de)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
|
ZA959469B
(en)
*
|
1994-11-15 |
1996-05-15 |
South African Druggists Ltd |
Pharmaceutical composition
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
AU5774796A
(en)
*
|
1995-06-13 |
1997-01-09 |
Dyer, Alison Margaret |
Pharmaceutical compositions containing lornoxicam and cyclod extrin
|
ES2243994T5
(es)
|
1996-04-19 |
2009-10-29 |
Grifols Inc. |
Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
AU709580B2
(en)
*
|
1996-08-09 |
1999-09-02 |
Alcon Laboratories, Inc. |
Preservative systems for pharmaceutical compositions containing cyclodextrins
|
DE19716120A1
(de)
*
|
1997-04-17 |
1998-10-22 |
Europ Lab Molekularbiolog |
Verwendung von cholesterinsenkenden Mitteln
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
JP4439596B2
(ja)
*
|
1997-06-13 |
2010-03-24 |
サイデクス ファーマシューティカルズ、 インク. |
長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
DE69834154T2
(de)
*
|
1997-07-01 |
2007-01-25 |
Pfizer Products Inc., Groton |
Verfahren zur Herstellung von einem Cyclodextrin
|
US6596706B1
(en)
*
|
1997-11-07 |
2003-07-22 |
Daiichi Pharmaceutical Co., Ltd. |
Piperazine-cyclodextrin complexes
|
US6699849B1
(en)
*
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
CA2320772A1
(en)
*
|
1998-02-23 |
1999-08-26 |
Cyclops, Ehf. |
High-energy cyclodextrin complexes
|
JP2002523475A
(ja)
*
|
1998-09-02 |
2002-07-30 |
アラーガン・セイルズ・インコーポレイテッド |
防腐したシクロデキストリン含有組成物
|
FR2784584B1
(fr)
*
|
1998-10-14 |
2002-09-20 |
Adir |
Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
|
US7375096B1
(en)
|
1998-12-04 |
2008-05-20 |
California Institute Of Technology |
Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
|
DE69935526T2
(de)
*
|
1998-12-04 |
2007-11-22 |
California Institute Of Technology, Pasadena |
Supramolekulare komplexe enthaltende arzneimittel
|
WO2000042849A1
(en)
|
1999-01-21 |
2000-07-27 |
Bristol-Myers Squibb Co. |
COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
GB9915231D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
AU7937500A
(en)
*
|
1999-10-27 |
2001-05-08 |
Farmarc Nederland Bv |
Pharmaceutical composition containing midazolam
|
EP1267941B1
(de)
*
|
2000-03-28 |
2005-11-23 |
Farmarc Nederland B.V. |
Alprazolam inklusion-komplexe und ihre pharmazeutischen zusammensetzungen
|
ATE416791T1
(de)
*
|
2000-05-02 |
2008-12-15 |
Theravance Inc |
Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
SI1284974T1
(en)
|
2000-05-26 |
2004-08-31 |
Pfizer Inc. |
Triazolyl tropane derivatives as ccr5 modulators
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
EP1307232B1
(de)
*
|
2000-08-03 |
2007-03-07 |
Antares Pharma IPL AG |
Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
US7198801B2
(en)
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
PE20020300A1
(es)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
WO2002055562A2
(en)
*
|
2001-01-11 |
2002-07-18 |
Eastman Chem Co |
Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
US6579898B2
(en)
|
2001-03-01 |
2003-06-17 |
Pfizer Inc. |
Compositions having improved bioavailability
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
PT1762567E
(pt)
*
|
2001-04-10 |
2012-07-16 |
Pfizer |
Derivados de pirazole para tratamento do vih
|
AP2003002900A0
(en)
*
|
2001-05-01 |
2003-12-31 |
Pfizer Prod Inc |
Method for manufacturing a low dose pharmaceutical composition
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
EP1269994A3
(de)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
US7008934B2
(en)
*
|
2001-06-28 |
2006-03-07 |
Baxter International Inc. |
Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
|
CA2452364A1
(en)
*
|
2001-06-29 |
2003-01-09 |
Maxygen Aps |
Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
HUP0401424A3
(en)
*
|
2001-07-20 |
2008-03-28 |
Dynamit Nobel Ag |
Nitrate ester-cyclodextrin complexes
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
BR0307332A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
WO2003068235A1
(en)
|
2002-02-11 |
2003-08-21 |
Pfizer Limited |
Nicotinamide derivatives useful as pde4 inhibitors
|
MXPA04008173A
(es)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
|
MXPA04008171A
(es)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Formulacion oftalmica con sistema de goma.
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
US6869939B2
(en)
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
US6818662B2
(en)
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
GB0212749D0
(en)
*
|
2002-06-01 |
2002-07-10 |
Boots Co Plc |
Personal care compositions
|
SI1542668T1
(sl)
*
|
2002-08-20 |
2009-08-31 |
Bristol Myers Squibb Co |
Aripiprazol sestavljena formulacija in postopek
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
CN104383554B
(zh)
|
2002-09-06 |
2018-06-08 |
天蓝制药公司 |
用于传递治疗剂的以环糊精为基础的聚合物
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
RU2359698C2
(ru)
*
|
2002-09-13 |
2009-06-27 |
Сайдекс, Инк. |
Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
IL152573A
(en)
*
|
2002-10-31 |
2009-11-18 |
Transpharma Medical Ltd |
A system for the transmission through the skin of a medical preparation against vomiting and nausea
|
IL152575A
(en)
*
|
2002-10-31 |
2008-12-29 |
Transpharma Medical Ltd |
A skin-to-skin transmission system of water-insoluble drugs
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
PT1572173E
(pt)
|
2002-12-13 |
2010-05-10 |
Warner Lambert Co |
Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
|
CA2513331A1
(en)
|
2003-01-14 |
2004-08-05 |
Teva Pharmaceutical Industries Ltd |
Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
|
EP1594434B1
(de)
*
|
2003-01-14 |
2016-09-07 |
Yeda Research and Development Co. |
Parenterale peptidformulierungen zur behandlung von systemischem lupus erythematodes
|
EP1460064A1
(de)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide als beta-2 Agonisten
|
EP2301549A1
(de)
*
|
2003-04-18 |
2011-03-30 |
Advanced Medicine Research Institute |
Mittel zur Behandlung von Krankheiten zur Aufbringung auf das Auge
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
BRPI0414105B8
(pt)
|
2003-09-03 |
2021-05-25 |
Askat Inc |
compostos de benzimidazolona com atividade agonista do receptor 5-ht4
|
ES2335284T3
(es)
|
2003-09-03 |
2010-03-24 |
Glaxo Group Limited |
Nuevo procedimiento para preparar derivados de pleuromutilina.
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6960300B2
(en)
*
|
2003-09-08 |
2005-11-01 |
Sami Labs Limited |
Process for preparing water soluble diterpenes and their applications
|
ATE449633T1
(de)
|
2003-09-12 |
2009-12-15 |
Pfizer |
Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
|
OA13266A
(en)
|
2003-10-03 |
2007-01-31 |
Pfizer |
Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation.
|
MXPA06003316A
(es)
|
2003-10-10 |
2006-06-08 |
Antares Pharma Ipl Ag |
Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
BRPI0416812A
(pt)
|
2003-11-21 |
2007-03-06 |
Combinatorx Inc |
métodos e reagentes para o tratamento de desordens inflamatórias
|
US20070020299A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
KR20070007076A
(ko)
|
2003-12-31 |
2007-01-12 |
사이덱스 인크 |
술포알킬 에테르 γ-시클로덱스트린 및코르티코스테로이드를 함유한 흡입용 제형
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
OA13361A
(en)
|
2004-01-22 |
2007-04-13 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases.
|
NZ548318A
(en)
|
2004-01-22 |
2009-03-31 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
AU2005223483B2
(en)
|
2004-03-18 |
2009-04-23 |
Zoetis Llc |
N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
EP1730103B1
(de)
|
2004-03-23 |
2010-05-26 |
Pfizer Limited |
Als adrenozeptor geeignete formamidderivate
|
CA2562411A1
(en)
|
2004-04-15 |
2005-11-10 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
KR101781166B1
(ko)
|
2004-04-23 |
2017-09-22 |
사이덱스 파마슈티칼스, 인크. |
술포알킬 에테르 시클로덱스트린 함유 분말의 제조 방법 및 그 분말
|
WO2005105763A1
(en)
|
2004-04-30 |
2005-11-10 |
Warner-Lambert Company Llc |
Substituted morpholine compounds for the treatment of central nervous system disorders
|
CN1980574A
(zh)
*
|
2004-05-06 |
2007-06-13 |
锡德克斯公司 |
包含舍曲林和磺基烷基醚环糊精的掩味的制剂
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
EP2564834A3
(de)
*
|
2004-05-10 |
2013-08-21 |
Onyx Therapeutics, Inc. |
Verbindungen zur Proteasomenzyminhibition
|
EP1595881A1
(de)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
WO2005123718A2
(en)
|
2004-06-15 |
2005-12-29 |
Pfizer Japan Inc. |
Benzimidazolone carboxylic acid derivatives
|
SI1778686T1
(sl)
|
2004-08-12 |
2009-02-28 |
Pfizer |
Derivati triazolopiridinilsulfanila kot inhibitorji P38 MAP kinaze
|
KR100859891B1
(ko)
|
2004-08-26 |
2008-09-23 |
화이자 인코포레이티드 |
단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
|
ITMI20041763A1
(it)
*
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
Nuove formulazioni iniettabili contenenti progesterone
|
JP2008518905A
(ja)
|
2004-11-02 |
2008-06-05 |
ファイザー株式会社 |
スルホニルベンゾイミダゾール誘導体
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
WO2006052921A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
WO2006052922A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
EP2260835B1
(de)
*
|
2004-12-07 |
2013-03-06 |
Onyx Therapeutics, Inc. |
Zusammensetzung zur Proteasomhemmung
|
EP1674098A1
(de)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
|
CA2614223A1
(en)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
A registry method and control system for dea schedule ii-v medicines
|
JP4521463B2
(ja)
|
2005-03-17 |
2010-08-11 |
ファイザー株式会社 |
疼痛の治療に有用なn−(n−スルホニルアミノメチル)シクロプロパンカルボキサミド誘導体
|
DE602006003416D1
(de)
|
2005-03-21 |
2008-12-11 |
Pfizer Ltd |
Substituierte triazolderivate als oxytocinantagonisten
|
AU2006236633B2
(en)
*
|
2005-04-15 |
2012-03-29 |
Albert Einstein College Of Medicine Of Yeshiva University |
Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
|
EP1874331B1
(de)
|
2005-04-19 |
2014-09-03 |
Kings College London |
Verwendung von bip gegen knochenverlust und osteoporose
|
TW200716106A
(en)
*
|
2005-04-24 |
2007-05-01 |
Wyeth Corp |
Methods for modulating bladder function
|
MX2007013780A
(es)
|
2005-05-04 |
2008-02-05 |
Pfizer Ltd |
Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
|
BRPI0610308A8
(pt)
|
2005-05-26 |
2017-04-25 |
Neuron Systems Inc |
Composições e métodos para o tratamento de doença retinal
|
WO2006125642A1
(en)
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
JPWO2006134877A1
(ja)
*
|
2005-06-13 |
2009-01-08 |
武田薬品工業株式会社 |
注射剤
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
EA200702497A1
(ru)
|
2005-06-15 |
2008-06-30 |
Пфайзер Лимитед |
Замещенные арилпиразолы для применения против паразитов
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
DE102005041860A1
(de)
*
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
|
US20100204178A1
(en)
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
PT1928464E
(pt)
|
2005-09-30 |
2014-07-10 |
Lundbeck Inc |
Nova formulação parentérica de carbamazepina
|
PL2581078T3
(pl)
*
|
2005-10-26 |
2015-07-31 |
Cydex Pharmaceuticals Inc |
Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
|
US7629331B2
(en)
*
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
PL2623113T3
(pl)
|
2005-11-09 |
2018-05-30 |
Onyx Therapeutics, Inc. |
Związek do hamowania enzymu
|
US7858609B2
(en)
|
2005-11-28 |
2010-12-28 |
Marinus Pharmaceuticals |
Solid ganaxolone formulations and methods for the making and use thereof
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
EP1971348A2
(de)
*
|
2005-12-20 |
2008-09-24 |
Tika Läkemedel AB |
Systeme und verfahren zur abgabe von corticosteroiden mit vermehrter lungenabscheidung
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
TW200734334A
(en)
*
|
2006-01-13 |
2007-09-16 |
Wyeth Corp |
Treatment of substance abuse
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
CA2642577A1
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Lakemedel Ab |
Methods of manufacturing corticosteroid solutions
|
BRPI0709133A2
(pt)
*
|
2006-03-24 |
2011-06-28 |
Wyeth Corp |
métodos para tratar distúrbios cognitivos e outros
|
AU2007230891A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for modulating bladder function
|
AU2007229491A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for treating cognitive and other disorders
|
WO2007112014A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
EP1998781A2
(de)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Schmerzbehandlung
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
MX2008013407A
(es)
*
|
2006-04-18 |
2009-03-09 |
Ekr Therapeutics Inc |
Composiciones de bolo iv premezcladas, listas para uso y metodos de uso.
|
NZ571460A
(en)
|
2006-04-21 |
2010-10-29 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
CN100374468C
(zh)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
水溶性磺烷基醚-β-环糊精的合成工艺
|
BRPI0713309A2
(pt)
|
2006-06-19 |
2012-04-17 |
Proteolix Inc |
compostos para inibição de enzimas
|
CA2656613A1
(en)
*
|
2006-07-03 |
2008-01-10 |
Genmab A/S |
Prevention of rash in patients undergoing anti-egfr therapy
|
AR061889A1
(es)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
Proceso mejorado para la preparacion de voriconazol
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
US20100022481A1
(en)
*
|
2006-08-02 |
2010-01-28 |
Dong Wang |
Drug Carriers, Their Synthesis, and Methods of Use Thereof
|
WO2008024914A2
(en)
|
2006-08-23 |
2008-02-28 |
Intellect Neurosciences Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
ES2532084T3
(es)
*
|
2006-09-15 |
2015-03-24 |
Regents Of The University Of Minnesota |
Composiciones de topiramato y métodos para su uso
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US20100093861A1
(en)
|
2006-09-15 |
2010-04-15 |
Stevia Aps |
Treatment of insulin resistance or diseases associated with insulin resistance
|
EP2081939B1
(de)
|
2006-09-21 |
2011-06-15 |
RaQualia Pharma Inc |
Benzimidazolderivate als selektive säurepumpenhemmer
|
US7744890B2
(en)
|
2006-10-12 |
2010-06-29 |
Wyeth Llc |
Methods and compositions with reduced opalescence
|
PL2076508T3
(pl)
|
2006-10-18 |
2011-05-31 |
Pfizer Prod Inc |
Związki biaryloeteru mocznika
|
MX2009004214A
(es)
|
2006-10-20 |
2009-05-11 |
Icos Corp |
Composiciones de inhibidores de chk1.
|
JP2010512305A
(ja)
|
2006-10-23 |
2010-04-22 |
ファイザー株式会社 |
置換フェニルメチルビシクロカルボキシアミド化合物
|
US8158609B1
(en)
*
|
2006-11-02 |
2012-04-17 |
Novartis Ag |
Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
|
JP5401319B2
(ja)
|
2006-11-03 |
2014-01-29 |
ワイス・エルエルシー |
細胞培養における解糖阻害物質
|
KR100822133B1
(ko)
*
|
2006-11-06 |
2008-04-15 |
한미약품 주식회사 |
비타민 d 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
|
JP2010510311A
(ja)
*
|
2006-11-21 |
2010-04-02 |
ノバルティス アーゲー |
ベンゾジアゼピン構造のrsv阻害剤を含む安定な非経腸製剤
|
US20080176958A1
(en)
|
2007-01-24 |
2008-07-24 |
Insert Therapeutics, Inc. |
Cyclodextrin-based polymers for therapeutics delivery
|
CA2679919C
(en)
*
|
2007-03-02 |
2015-12-15 |
University Of Wollongong |
Compositions and methods for delivery of anti-cancer agents
|
DK2115126T3
(en)
|
2007-03-02 |
2015-05-04 |
Wyeth Llc |
Use of copper and glutamate in cell culture for the preparation of polypeptides
|
AU2015255164B2
(en)
*
|
2007-04-27 |
2017-06-08 |
Cydex Pharmaceuticals, Inc. |
Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
|
NZ581362A
(en)
*
|
2007-04-27 |
2011-07-29 |
Cydex Pharmaceuticals Inc |
Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
EP2160381A2
(de)
*
|
2007-05-24 |
2010-03-10 |
Pfizer Limited |
Spirocyclische quinazolin derivate und ihre verwendung als pde7 hemmer
|
CA2689016C
(en)
|
2007-05-25 |
2014-08-12 |
Ipsen Pharma S.A.S. |
Melanocortin receptor ligands modified with hydantoin
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
TWI428132B
(zh)
*
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
WO2009031011A2
(en)
|
2007-09-05 |
2009-03-12 |
Pfizer Limited |
Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
|
KR100929920B1
(ko)
|
2007-09-05 |
2009-12-04 |
주식회사 마크로케어 |
사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
MY166950A
(en)
|
2007-10-04 |
2018-07-25 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
EP2057982A1
(de)
|
2007-11-09 |
2009-05-13 |
Archimedes Development Limited |
Intranasale Zusammensetzungen
|
US8040246B2
(en)
*
|
2007-12-04 |
2011-10-18 |
Avaya Inc. |
Systems and methods for facilitating a first response mission at an incident scene
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
WO2009137611A2
(en)
*
|
2008-05-06 |
2009-11-12 |
Board Of Regents, The University Of Texas System |
Treatment of pulmonary fungal infection with voriconazole via inhalation
|
US20110144202A1
(en)
*
|
2008-06-16 |
2011-06-16 |
Uwe Marx |
Concentrated oxaliplatin solution and its method of preparation
|
US20100022635A1
(en)
*
|
2008-07-28 |
2010-01-28 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
ATE542813T1
(de)
|
2008-08-06 |
2012-02-15 |
Pfizer |
6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
|
EP2163253B1
(de)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
|
US20100093872A1
(en)
*
|
2008-10-15 |
2010-04-15 |
Erimos Pharmaceuticals Llc |
Stable aqueous formulations of water insoluble or poorly soluble drugs
|
EA024364B1
(ru)
|
2008-10-21 |
2016-09-30 |
Оникс Терапьютикс, Инк. |
Способ лечения множественной миеломы
|
WO2010053487A1
(en)
|
2008-11-07 |
2010-05-14 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
AU2009314072C1
(en)
|
2008-11-15 |
2016-11-10 |
Melinta Subsidiary Corp. |
Antimicrobial compositions
|
KR101637337B1
(ko)
|
2008-11-21 |
2016-07-07 |
라퀄리아 파마 인코포레이티드 |
5-ht2b 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체
|
SG172219A1
(en)
|
2008-12-17 |
2011-07-28 |
Genentech Inc |
Hepatitis c virus combination therapy
|
KR101345497B1
(ko)
|
2009-01-12 |
2013-12-31 |
이카겐, 인코포레이티드 |
설폰아미드 유도체
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
PT2387580E
(pt)
|
2009-01-14 |
2014-10-30 |
Novacta Biosystems Ltd |
Derivativos da desoxiactagardina
|
BRPI1007884A2
(pt)
|
2009-02-04 |
2016-09-06 |
Novacta Biosystems Ltd |
derivados de actagardina
|
JP5749659B2
(ja)
|
2009-03-12 |
2015-07-15 |
ハーゼ インベストメンツ ウーゲー |
Bmpアンタゴニスト感受性が低下した骨形成タンパク質2(bmp2)変異体
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
EP2233502A1
(de)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
HUE047755T2
(hu)
|
2009-05-13 |
2020-05-28 |
Cydex Pharmaceuticals Inc |
Prasugrelt és ciklodextrin-származékokat tartalmazó gyógyszerkészítmények, eljárás ezek elõállítására és alkalmazásra
|
CA2760284A1
(en)
|
2009-05-29 |
2010-12-02 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
US20100311838A1
(en)
|
2009-05-29 |
2010-12-09 |
Pipkin James D |
Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
EP2266563A1
(de)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
|
SI2442791T1
(sl)
|
2009-06-16 |
2020-03-31 |
Pfizer Inc. |
Dozirna oblika apiksabana
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
WO2011041593A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
EP2516434B1
(de)
|
2009-12-23 |
2015-05-27 |
Takeda Pharmaceutical Company Limited |
Geschmolzene heteroaromatische pyrrolidinone als syk-hemmer
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
BR112012017800B1
(pt)
|
2010-01-21 |
2020-12-08 |
Drawbridge Pharmaceuticals Pty Ltd |
composição anestésica ou sedativa
|
JP5852966B2
(ja)
|
2010-02-02 |
2016-02-03 |
ノヴァクタ バイオシステムズ リミティッド |
ランチビオティックの塩
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
CA2789606A1
(en)
|
2010-02-25 |
2011-09-01 |
Pfizer Limited |
Peptide analogues as opioid receptor agonists
|
EP2542238B1
(de)
|
2010-03-01 |
2015-08-12 |
Onyx Therapeutics, Inc. |
Verbindungen zur immunproteasomhemmung
|
EP3513660A1
(de)
*
|
2010-03-13 |
2019-07-24 |
Eastpond Laboratories Limited |
Fettbindende zusammensetzungen
|
BR112012025264A2
(pt)
|
2010-04-07 |
2019-09-24 |
Onyx Therapeutics Inc |
inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
|
US8916593B2
(en)
|
2010-05-04 |
2014-12-23 |
Pfizer Inc. |
Alkoxy-substituted 2-aminopyridines as ALK inhibitors
|
AU2011258964B2
(en)
|
2010-05-26 |
2015-04-16 |
Neurophyxia B.V. |
2-iminobiotin formulations and uses thereof
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
AU2011264919A1
(en)
*
|
2010-06-11 |
2013-01-10 |
Baxter Healthcare S.A. |
Formulations including amiodarone and salts thereof and methods of their manufacture and use
|
EP2590972B1
(de)
|
2010-07-09 |
2015-01-21 |
Pfizer Limited |
N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
|
JP5860045B2
(ja)
|
2010-07-09 |
2016-02-16 |
ファイザー・リミテッドPfizer Limited |
化合物
|
EP2590951B1
(de)
|
2010-07-09 |
2015-01-07 |
Pfizer Limited |
Benzolsulfonamide als kaliumkanalhemmer
|
CA2804351A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
CA2800971A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
EP2593432B1
(de)
|
2010-07-12 |
2014-10-22 |
Pfizer Limited |
N-sulfonylbenzamidderivate als spannungsgesteuerte natriumkanalhemmer
|
US9096500B2
(en)
|
2010-07-12 |
2015-08-04 |
Pfizer Limited |
Acyl sulfonamide compounds
|
EP2593427B1
(de)
|
2010-07-12 |
2014-12-24 |
Pfizer Limited |
Sulfonamidderivate als nav1.7-inhibitoren zur schmerzbehandlung
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
BR112013004275A2
(pt)
|
2010-08-24 |
2016-08-02 |
Imp Innovations Ltd |
glicodendrímeros de polipropileterimina
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
EP2635121B1
(de)
|
2010-11-01 |
2020-01-08 |
MEI Pharma, Inc. |
Isoflavonoidverbindungen und verfahren zur behandlung von krebs
|
EP2640729B1
(de)
|
2010-11-15 |
2016-12-21 |
VIIV Healthcare UK Limited |
Hiv-replikationshemmer
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
UA114705C2
(uk)
|
2011-01-26 |
2017-07-25 |
Аллерган, Інк. |
Андрогенна композиція для лікування офтальмологічного захворювання
|
US8791107B2
(en)
|
2011-02-25 |
2014-07-29 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
BR112013025792A2
(pt)
|
2011-04-05 |
2018-04-24 |
Pfizer Ltd |
Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
|
ES2618494T3
(es)
|
2011-05-18 |
2017-06-21 |
Raqualia Pharma Inc |
Forma polimórfica del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro -2H-piran-4-carboxílico
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
RU2566262C2
(ru)
|
2011-06-15 |
2015-10-20 |
Синтон Бв |
Стабилизированная композиция вориконазола
|
EP2723739B1
(de)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituierte 6-aza-isoindolin-1-on-derivate
|
ES2564366T3
(es)
|
2011-07-13 |
2016-03-22 |
Pfizer Limited |
Análogos de encefalina
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
AU2012291744A1
(en)
|
2011-08-02 |
2014-02-20 |
Pfizer Inc. |
Crizotinib for use in the treatment of cancer
|
WO2013017136A1
(en)
|
2011-08-02 |
2013-02-07 |
Pensieve Biosciences Cyprus Limited |
Treatment of cognitive impairment
|
SI2753632T1
(sl)
|
2011-09-08 |
2023-08-31 |
Sage Therapeutics, Inc. |
Nevroaktivni steroidi, njihovi sestavki in uporaba
|
EP2758052B9
(de)
|
2011-09-18 |
2019-03-27 |
Euro-Celtique S.A. |
HDAC-Hemmer-Cyclopolysaccharidzusammensetzung
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
CA3152410A1
(en)
|
2011-10-14 |
2013-04-18 |
Sage Therapeutics, Inc. |
3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
WO2013061205A2
(en)
|
2011-10-26 |
2013-05-02 |
Pfizer Limited |
Chemical compounds
|
EP3243815B1
(de)
|
2011-10-28 |
2019-07-10 |
Inhibitaxin Limited |
Pyridazinderivate für therapeutische zwecke
|
ES2593533T3
(es)
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
TW201332572A
(zh)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
具有經取代的β-環糊精之藥物製劑
|
US20150291514A1
(en)
|
2012-01-04 |
2015-10-15 |
Pfizer Limted |
N-Aminosulfonyl Benzamides
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
WO2013114250A1
(en)
|
2012-02-03 |
2013-08-08 |
Pfizer Inc. |
Benziimidazole and imidazopyridine derivatives as sodium channel modulators
|
TW201336527A
(zh)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
JP6508944B2
(ja)
|
2012-02-15 |
2019-05-08 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
シクロデキストリン誘導体のための製造方法
|
CA2865950C
(en)
|
2012-02-28 |
2016-12-20 |
Cydex Pharmaceuticals, Inc. |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
MX350844B
(es)
|
2012-03-06 |
2017-09-22 |
Pfizer |
Derivados macrocíclicos para el tratamiento de enfermedades proliferativas.
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
JP6081572B2
(ja)
|
2012-03-30 |
2017-02-15 |
ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH |
アントシアニジン複合体
|
JP2015524394A
(ja)
|
2012-07-09 |
2015-08-24 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
|
TW201414734A
(zh)
|
2012-07-10 |
2014-04-16 |
Takeda Pharmaceutical |
氮雜吲哚衍生物
|
CN104684585A
(zh)
|
2012-08-03 |
2015-06-03 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗溶酶体贮积症的环糊精
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
WO2014045029A1
(en)
|
2012-09-18 |
2014-03-27 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
JP6254169B2
(ja)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
US20140094432A1
(en)
|
2012-10-02 |
2014-04-03 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
WO2014053967A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
JP2015531393A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
トロポミオシン関連キナーゼ阻害剤
|
EP2912036A1
(de)
|
2012-10-04 |
2015-09-02 |
Pfizer Limited |
Pyrrolo[3,2-d-]pyrimidin-tropomyosin-vermittelte kinasehemmer
|
WO2014060548A1
(de)
*
|
2012-10-17 |
2014-04-24 |
Sapiotec Gmbh |
Anthocyanidin-komplex zur behandlung von multiplem myelom
|
EP2909239A4
(de)
|
2012-10-22 |
2016-06-08 |
Cydex Pharmaceuticals Inc |
Alkylierte zusammensetzungen auf basis von cyclodextrin und verfahren zur herstellung und gebrauch derselben
|
KR20150065191A
(ko)
|
2012-11-08 |
2015-06-12 |
화이자 인코포레이티드 |
헤테로방향족 화합물 및 도파민 d1 리간드로서 이의 용도
|
KR101660664B1
(ko)
|
2012-11-08 |
2016-09-27 |
화이자 인코포레이티드 |
도파민 d1 리간드로서의 헤테로방향족 화합물
|
EP2919791B1
(de)
*
|
2012-11-15 |
2017-03-22 |
SapioTec GmbH |
Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
|
CA2890861C
(en)
|
2012-11-21 |
2021-03-30 |
Raqualia Pharma Inc. |
Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
|
AP2015008444A0
(en)
|
2012-12-03 |
2015-05-31 |
Pfizer |
Novel selective androgen receptor modulators
|
US9511047B2
(en)
*
|
2012-12-11 |
2016-12-06 |
Sapiotec Gmbh |
Delphinidin for combating melanoma cells
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
EP2948149A4
(de)
|
2013-01-23 |
2016-12-14 |
Aldeyra Therapeutics Inc |
Durch toxisches aldehyd bedingte erkrankungen und behandlung
|
WO2014128588A1
(en)
|
2013-02-21 |
2014-08-28 |
Pfizer Inc. |
Solid forms of a selective cdk4/6 inhibitor
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
US20160031930A1
(en)
|
2013-03-13 |
2016-02-04 |
Sage Therapeutics, Inc. |
Neuroactive steroids and methods of use thereof
|
MX2015012437A
(es)
|
2013-03-13 |
2016-04-15 |
Sage Therapeutics Inc |
Esteroides neuroactivos, composiciones, y usos de los mismos.
|
EP2784083A1
(de)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
|
PL3498725T3
(pl)
|
2013-04-17 |
2021-11-08 |
Sage Therapeutics, Inc. |
19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii
|
CN112110976B
(zh)
|
2013-04-17 |
2023-08-29 |
萨奇治疗股份有限公司 |
刺激神经活性的19-去甲类固醇及其使用方法
|
EP2792360A1
(de)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
PL3421462T3
(pl)
|
2013-06-27 |
2023-09-11 |
Pfizer Inc. |
Związki heteroaromatyczne i ich zastosowanie jako ligandów dopaminy d1
|
AU2014287496A1
(en)
|
2013-07-08 |
2016-01-07 |
Abbvie, Inc. |
Stabilized pharmaceutical dosage forms comprising atrasentan
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
PT3021852T
(pt)
|
2013-07-19 |
2021-04-21 |
Sage Therapeutics Inc |
Esteroides neuroativos, composições e utilizações das mesmas
|
WO2015027227A1
(en)
|
2013-08-23 |
2015-02-26 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
RU2572334C2
(ru)
*
|
2013-12-06 |
2016-01-10 |
Общество С Ограниченной Ответственностью "Луфатен" |
Клатратный комплекс арабиногалактана или гуммиарабика с 20-гидроксиэкдизоном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
|
CA2934010A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2015106012A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
CN104971355B
(zh)
*
|
2014-04-02 |
2018-04-24 |
上海现代药物制剂工程研究中心有限公司 |
含有利伐沙班的组合物及其制备方法
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
US9868744B2
(en)
|
2014-04-25 |
2018-01-16 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
PE20170009A1
(es)
|
2014-04-25 |
2017-03-17 |
Pfizer |
Compuestos heteroaromaticos y su uso como ligandos de dopamina d1
|
CR20160493A
(es)
|
2014-04-25 |
2016-12-16 |
Pfizer |
Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
|
US9856263B2
(en)
|
2014-04-28 |
2018-01-02 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
JP6564394B2
(ja)
|
2014-04-28 |
2019-08-21 |
ファイザー・インク |
複素環式化合物およびそのドーパミンd1リガンドとしての使用
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
KR20170002623A
(ko)
|
2014-05-14 |
2017-01-06 |
화이자 인코포레이티드 |
피라졸로피리딘 및 피라졸로피리미딘
|
MX371014B
(es)
|
2014-05-15 |
2020-01-10 |
Pfizer |
Forma cristalina de 6-[(4r)-4-metil-1,2-dióxido-1,2,6-tiadiazinan- 2-il]isoquinolin-1-carbonitrilo.
|
KR102471082B1
(ko)
|
2014-05-20 |
2022-11-25 |
라퀄리아 파마 인코포레이티드 |
벤즈이소옥사졸 유도체염
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
AR100691A1
(es)
|
2014-05-29 |
2016-10-26 |
Sage Therapeutics Inc |
Esteroides neuroactivos, composiciones, y usos de los mismos
|
WO2015181797A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
ES2864079T3
(es)
|
2014-05-30 |
2021-10-13 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
|
EP3154979B1
(de)
|
2014-06-12 |
2018-03-07 |
Pfizer Limited |
Imidazopyridazinderivate als modulatoren der gabaa-rezeptoraktivität
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
GEP20186933B
(en)
|
2014-06-17 |
2018-12-10 |
Pfizer |
Substituted dihydroisoquinoline compounds
|
NZ725354A
(en)
|
2014-06-18 |
2018-05-25 |
Elanco Us Inc |
Transdermal formulations of pergolide and uses thereof
|
WO2015195967A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
DK3183295T3
(da)
|
2014-08-22 |
2023-08-21 |
Cydex Pharmaceuticals Inc |
Fraktioneret alkyleret cyclodextrinsammensætning og fremgangsmåder til fremstilling og anvendelse af samme
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
WO2016044433A2
(en)
|
2014-09-16 |
2016-03-24 |
Biopharma Works |
Metformin derivatives
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
EP3204011A4
(de)
|
2014-10-07 |
2018-06-20 |
Sage Therapeutics, Inc. |
Neuroaktive verbindungen und verfahren zur verwendung davon
|
JP6742308B2
(ja)
|
2014-10-16 |
2020-08-19 |
セージ セラピューティクス, インコーポレイテッド |
Cns障害を処置するための組成物および方法
|
SG10202009861SA
(en)
|
2014-10-16 |
2020-11-27 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
ES2793237T3
(es)
|
2014-11-27 |
2020-11-13 |
Sage Therapeutics Inc |
Composiciones y métodos para el tratamiento de trastornos del SNC
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
NZ734714A
(en)
|
2015-01-22 |
2023-07-28 |
Phytoplant Res S L |
Methods of purifying cannabinoids, compositions and kits thereof
|
EP3050574B1
(de)
|
2015-01-28 |
2019-10-09 |
Universite De Bordeaux |
Verwendung von Plerixafor zur Behandlung und/oder Vorbeugung von akuten Exazerbationen einer chronisch obstruktiver Lungenerkrankung
|
HUE054998T2
(hu)
|
2015-02-02 |
2021-10-28 |
Mei Pharma Inc |
Kombinációs terápiák emlõrák kezelésében való alkalmazásra
|
CN115381772A
(zh)
|
2015-02-06 |
2022-11-25 |
马瑞纳斯制药公司 |
静脉内加奈索酮制剂及其用途
|
EP3258939B1
(de)
|
2015-02-20 |
2022-09-07 |
Sage Therapeutics, Inc. |
Neuroaktive steroide, zusammensetzungen und verwendungen davon
|
TN2017000357A1
(en)
|
2015-02-24 |
2019-01-16 |
Pfizer |
Substituted nucleoside derivatives useful as anticancer agents
|
CA2979527A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
|
MX2017011966A
(es)
|
2015-03-19 |
2018-06-06 |
Cydex Pharmaceuticals Inc |
Composiciones que contienen silimarina y sulfoalquil eter ciclodextrina y metodos de uso de las mismas.
|
US20180311258A1
(en)
|
2015-04-10 |
2018-11-01 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
AU2016276774A1
(en)
|
2015-06-10 |
2018-01-18 |
Vtesse, Inc. |
Hydroxypropyl beta-cyclodextrin compositions and methods
|
CA2991313C
(en)
|
2015-07-06 |
2023-12-19 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
PL3319611T3
(pl)
|
2015-07-06 |
2021-07-12 |
Sage Therapeutics, Inc. |
Oksysterole i sposoby ich stosowania
|
EP3319610A4
(de)
|
2015-07-06 |
2019-03-06 |
Sage Therapeutics, Inc. |
Oxysterole und verfahren zur verwendung davon
|
US20170007617A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences Drive |
Intravenous formulations of a late sodium current inhibitor
|
CU20170166A7
(es)
|
2015-07-31 |
2018-03-13 |
Pfizer |
Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1, 1, 1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl
|
EP3337486B1
(de)
|
2015-08-21 |
2024-04-03 |
Aldeyra Therapeutics, Inc. |
Deuterierte verbindungen und verwendungen davon
|
US10538523B2
(en)
|
2015-12-10 |
2020-01-21 |
Pfizer Limited |
4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
|
TWI722080B
(zh)
|
2015-12-24 |
2021-03-21 |
日商武田藥品工業股份有限公司 |
共結晶、其製造方法及含有共結晶的醫藥
|
EP3399968B8
(de)
|
2016-01-07 |
2021-12-01 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
MX2018008653A
(es)
|
2016-01-15 |
2018-12-10 |
Pfizer |
Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
|
RU2018129076A
(ru)
|
2016-02-18 |
2020-03-18 |
Мелинта Терапьютикс, Инк. |
Составы оритаванцина
|
JP7450242B2
(ja)
|
2016-02-28 |
2024-03-15 |
アルデイラ セラピューティクス, インコーポレイテッド |
シクロデキストリンを用いるアレルギーの眼の状態の処置
|
JP7112957B2
(ja)
|
2016-03-09 |
2022-08-04 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
腫瘍細胞懸濁培養及び関連方法
|
US20190105407A1
(en)
*
|
2016-03-31 |
2019-04-11 |
Takeda Pharmaceutical Company Limited |
Isoquinolinyl triazolone complexes
|
DK3436022T3
(da)
|
2016-04-01 |
2022-06-20 |
Sage Therapeutics Inc |
Oxysteroler og fremgangsmåder til anvendelse heraf
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
MX2018013472A
(es)
|
2016-05-09 |
2019-02-28 |
Aldeyra Therapeutics Inc |
Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
|
US20190030170A1
(en)
*
|
2016-05-10 |
2019-01-31 |
Vireo Health LLC |
Cannabinoid formulations with improved solubility
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
WO2018009867A1
(en)
|
2016-07-07 |
2018-01-11 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
JP7049313B2
(ja)
|
2016-07-11 |
2022-04-06 |
セージ セラピューティクス, インコーポレイテッド |
C17、c20、およびc21置換神経刺激性ステロイドおよびそれらの使用方法
|
US20190233465A1
(en)
|
2016-07-11 |
2019-08-01 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
EP3491005A1
(de)
|
2016-07-29 |
2019-06-05 |
Pfizer Inc |
Cyclische peptide als c5-a-rezeptorantagonisten
|
AU2017311412B2
(en)
|
2016-08-11 |
2023-05-18 |
Ovid Therapeutics Inc. |
Methods and compositions for treatment of epileptic disorders
|
RU2726115C1
(ru)
|
2016-08-15 |
2020-07-09 |
Пфайзер Инк. |
Пиридопиримидиновые ингибиторы cdk2/4/6
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
JP7149266B2
(ja)
|
2016-09-30 |
2022-10-06 |
セージ セラピューティクス, インコーポレイテッド |
C7置換オキシステロールおよびnmdaモジュレーターとしての方法
|
CA3040155C
(en)
|
2016-10-11 |
2024-01-16 |
Euro-Celtique S.A. |
Compound for use in the treatment of hodgkin lymphoma
|
AU2017345399B2
(en)
|
2016-10-18 |
2022-02-24 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
JP7118957B2
(ja)
|
2016-10-18 |
2022-08-16 |
セージ セラピューティクス, インコーポレイテッド |
オキシステロールおよびその使用方法
|
EP3541364A1
(de)
|
2016-11-18 |
2019-09-25 |
AiCuris Anti-infective Cures GmbH |
Neuartige formulierungen von amidinsubstituierten beta-lactam-verbindungen auf basis von modifizierten cyclodextrinen und ansäuerungsmitteln, deren herstellung und verwendung als antimikrobielle pharmazeutische zusammensetzungen
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
EP4252856A3
(de)
|
2016-12-20 |
2024-01-24 |
Oligomerix, Inc. |
Neuartige chinazolinone zur hemmung der bildung von tau-oligomeren und deren verfahren zur verwendung
|
WO2018133827A1
(zh)
|
2017-01-20 |
2018-07-26 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
|
KR20190104405A
(ko)
|
2017-01-20 |
2019-09-09 |
화이자 인코포레이티드 |
Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체
|
JP6778833B2
(ja)
|
2017-01-20 |
2020-11-04 |
深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. |
キナーゼ活性を抑制するための(ヘテロ)アリールアミド類化合物
|
AU2018208848A1
(en)
|
2017-01-23 |
2019-07-18 |
Pfizer Inc., |
Heterocyclic spiro compounds as MAGL inhibitors
|
US11274164B2
(en)
|
2017-02-07 |
2022-03-15 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Method for the preparation of sulfobutylether beta cyclodextrin sodium
|
AU2018234919A1
(en)
|
2017-03-16 |
2019-09-19 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
AU2018244211B2
(en)
|
2017-03-26 |
2022-05-12 |
Takeda Pharmaceutical Company Limited |
Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
|
EP3608321B1
(de)
|
2017-04-01 |
2022-09-07 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1h-imidazo[4,5-h]chinazolin-verbindung als proteinkinaseinhibitor
|
JP7204670B2
(ja)
|
2017-05-03 |
2023-01-16 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
シクロデキストリン及びブスルファンを含有する組成物
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
MX2019015468A
(es)
|
2017-06-22 |
2020-08-03 |
Curadev Pharma Ltd |
Moduladores de moleculas pequeñas de sting humana.
|
JP7374496B2
(ja)
|
2017-06-26 |
2023-11-07 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
Bcl-2タンパク質を阻害するためのN-ベンゼンスルホニルベンズアミド系化合物、その組成物および使用
|
WO2019001379A1
(zh)
|
2017-06-26 |
2019-01-03 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制激酶活性的吲唑类化合物及其组合物及应用
|
EP3651734A1
(de)
|
2017-07-11 |
2020-05-20 |
Gilead Sciences, Inc. |
Zusammensetzungen mit einem rna-polymerasehemmer und cyclodextrin zur behandlung von virusinfektionen
|
EP3666774B1
(de)
|
2017-08-11 |
2022-05-11 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1h-pyrazolo[4,3-h]chinazolinverbindung als proteinkinaseinhibitor
|
JP6985764B2
(ja)
|
2017-08-30 |
2021-12-22 |
深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. |
アミノピリミジン系化合物、この化合物を含む組成物およびそれらの使用
|
WO2019043634A2
(en)
|
2017-08-30 |
2019-03-07 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
|
CN110997637B
(zh)
|
2017-09-05 |
2022-09-27 |
保仕健生物科技(上海)有限公司 |
芳香类衍生物、其制备方法及其在医药上的应用
|
CA3074304A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
CA3077362A1
(en)
|
2017-10-10 |
2019-04-18 |
Aldeyra Therapeutics, Inc. |
Treatment of inflammatory disorders
|
WO2019075362A1
(en)
|
2017-10-12 |
2019-04-18 |
Sage Therapeutics, Inc. |
METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
|
MA51046A
(fr)
|
2017-12-08 |
2021-03-17 |
Sage Therapeutics Inc |
Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
|
CN109320553A
(zh)
|
2017-12-21 |
2019-02-12 |
深圳市塔吉瑞生物医药有限公司 |
用于抗病毒的新型核苷类逆转录酶抑制剂
|
US11254696B2
(en)
|
2017-12-21 |
2022-02-22 |
Shenzhen Targetrx, Inc. |
Dianilinopyrimidine compound for inhibiting kinase activity
|
JP7085242B2
(ja)
|
2017-12-21 |
2022-06-16 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
キナーゼ活性を阻害するためのアリールホスフィンオキシド
|
WO2019120084A1
(zh)
|
2017-12-21 |
2019-06-27 |
深圳市塔吉瑞生物医药有限公司 |
用于抗病毒的核苷类逆转录酶抑制剂
|
AU2018388408B2
(en)
|
2017-12-22 |
2023-12-21 |
Sage Therapeutics, Inc. |
Compositions and methods for treating CNS disorders
|
US20220315621A1
(en)
|
2017-12-22 |
2022-10-06 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
JP2021510695A
(ja)
|
2018-01-12 |
2021-04-30 |
セージ セラピューティクス, インコーポレイテッド |
CNS障害の処置における使用のためのアザ、オキサ、およびチア−プレグナン−20−オン−3α−オール化合物
|
CA3089490A1
(en)
|
2018-01-29 |
2019-08-01 |
Phytoplant Research S.L |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
PE20211313A1
(es)
|
2018-03-01 |
2021-07-22 |
Takeda Pharmaceuticals Co |
Piperidinil-3-(ariloxi)propanamidas y propanoatos
|
TWI741268B
(zh)
|
2018-03-15 |
2021-10-01 |
美商輝瑞股份有限公司 |
干擾素基因刺激劑(sting)的環戊烷為主體之調節劑
|
US11459334B2
(en)
|
2018-04-16 |
2022-10-04 |
Shenzhen Targetrx, Inc. |
Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
|
CN110386944B
(zh)
|
2018-04-16 |
2021-10-29 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制蛋白激酶活性的二(杂)芳基大环化合物
|
JP7089061B2
(ja)
|
2018-04-26 |
2022-06-21 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤としての2-アミノ-ピリジンまたは2-アミノ-ピリミジン誘導体
|
CN112218627B
(zh)
|
2018-05-30 |
2024-04-16 |
康维尔特制药有限公司 |
前药及其在医学上的应用
|
US20210212321A1
(en)
|
2018-06-01 |
2021-07-15 |
Bayer Cropscience Lp |
Stabilized fungicidal composition comprising cyclodextrin
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
CN110194772B
(zh)
|
2018-07-02 |
2022-04-05 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制蛋白激酶活性的炔基(杂)芳环类化合物
|
WO2020011141A1
(zh)
|
2018-07-12 |
2020-01-16 |
深圳市塔吉瑞生物医药有限公司 |
一种二芳基吡唑化合物及包含该化合物的组合物及其用途
|
US11746110B2
(en)
|
2018-07-17 |
2023-09-05 |
Shenzhen Targetrx, Inc. |
Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
|
US20210309669A1
(en)
|
2018-07-19 |
2021-10-07 |
Pfizer Inc. |
Heterocyclic Spiro Compounds As MAGL Inhibitors
|
EP3833660A4
(de)
|
2018-08-06 |
2022-05-11 |
Aldeyra Therapeutics, Inc. |
Polymorphe verbindungen und verwendungen davon
|
US11197821B2
(en)
|
2018-09-25 |
2021-12-14 |
Aldeyra Therapeutics, Inc. |
Formulations for treatment of dry eye disease
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
JP7352981B2
(ja)
|
2018-10-10 |
2023-09-29 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
|
DK3864022T3
(da)
|
2018-10-12 |
2023-12-18 |
Sage Therapeutics Inc |
Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser
|
EP3867261A1
(de)
|
2018-10-19 |
2021-08-25 |
Sage Therapeutics, Inc. |
9(11)-ungesättigte neuroaktive steroide und deren verwendungen
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
SG11202104585YA
(en)
|
2018-11-29 |
2021-06-29 |
Pfizer |
Pyrazoles as modulators of hemoglobin
|
WO2020118060A1
(en)
|
2018-12-05 |
2020-06-11 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
WO2020114388A1
(zh)
|
2018-12-06 |
2020-06-11 |
深圳市塔吉瑞生物医药有限公司 |
取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
US20220372067A1
(en)
|
2018-12-21 |
2022-11-24 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
JP7240032B2
(ja)
|
2018-12-21 |
2023-03-15 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
プロテインキナーゼ活性を阻害するためのアミノピリミジン系化合物
|
WO2020141224A1
(en)
|
2019-01-04 |
2020-07-09 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
WO2020150210A1
(en)
|
2019-01-14 |
2020-07-23 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Tetrazolone substituted steroids and use thereof
|
CN113330015A
(zh)
|
2019-01-23 |
2021-08-31 |
辉瑞大药厂 |
已知四氢异喹啉衍生物的单磷酸盐水合物盐的多晶型物形式
|
AU2020213761C1
(en)
|
2019-01-31 |
2023-08-10 |
Pfizer Inc. |
3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
|
CN111574521A
(zh)
|
2019-02-18 |
2020-08-25 |
深圳市塔吉瑞生物医药有限公司 |
取代的芳香稠合环衍生物及其组合物及用途
|
US11802113B2
(en)
|
2019-02-27 |
2023-10-31 |
Shenzhen Targetrx, Inc. |
Substituted pyrazole compounds, compositions containing same, and use thereof
|
TW202102498A
(zh)
|
2019-03-22 |
2021-01-16 |
日商武田藥品工業股份有限公司 |
作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
|
US11786518B2
(en)
|
2019-03-26 |
2023-10-17 |
Aldeyra Therapeutics, Inc. |
Ophthalmic formulations and uses thereof
|
WO2020198583A1
(en)
|
2019-03-27 |
2020-10-01 |
Insilico Medicine Ip Limited |
Bicyclic jak inhibitors and uses thereof
|
PE20220425A1
(es)
|
2019-04-29 |
2022-03-29 |
Solent Therapeutics Llc |
Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
|
AR119047A1
(es)
|
2019-05-31 |
2021-11-17 |
Sage Therapeutics Inc |
Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
|
EP3967694A4
(de)
|
2019-06-06 |
2022-12-07 |
Beijing Tide Pharmaceutical Co., Ltd. |
2, 4, 6-tri-substituierte pyrimidinverbindung als atr-kinase-inhibitor
|
US20230257415A1
(en)
|
2019-06-27 |
2023-08-17 |
Sage Therapeutics, Inc. |
Compounds for treating cns disorders
|
US20230085354A1
(en)
|
2019-06-27 |
2023-03-16 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
TW202114700A
(zh)
|
2019-06-27 |
2021-04-16 |
美商賽吉醫療公司 |
用於治療cns病症之組合物及方法
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
CA3147407A1
(en)
|
2019-07-25 |
2021-01-28 |
Curadev Pharma Pvt. Ltd. |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
WO2021026124A1
(en)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treatment of status epilepticus
|
EP4010031A1
(de)
|
2019-08-06 |
2022-06-15 |
L.E.A.F Holdings Group LLC |
Verfahren zur herstellung von polyglutamat-antifolaten und ihre verwendungen
|
JP2022546375A
(ja)
|
2019-08-23 |
2022-11-04 |
北京泰徳製薬股▲フン▼有限公司 |
Egfrおよびalkを阻害してそれらの分解を阻害する化合物
|
TW202124386A
(zh)
|
2019-09-16 |
2021-07-01 |
日商武田藥品工業股份有限公司 |
唑稠合之嗒-3(2h)-酮衍生物
|
JP2022550297A
(ja)
|
2019-09-25 |
2022-12-01 |
ファイザー・インク |
Sting(インターフェロン遺伝子刺激因子)のヘテロ多環式モジュレーター
|
BR112022005674A2
(pt)
|
2019-09-26 |
2022-06-21 |
Shenzhen Targetrx Inc |
Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo
|
US20230028221A1
(en)
|
2019-11-01 |
2023-01-26 |
Shanghaitech University |
Eed inhibitor, and preparation method therefor and use thereof
|
CN114828889A
(zh)
|
2019-12-06 |
2022-07-29 |
马瑞纳斯制药公司 |
用于治疗结节性硬化症的加奈索酮
|
JP2023506086A
(ja)
|
2019-12-16 |
2023-02-14 |
北京泰徳製薬股▲フン▼有限公司 |
Egfrキナーゼを阻害してその分解を誘導する化合物
|
WO2021143762A1
(en)
|
2020-01-17 |
2021-07-22 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
Novel compounds as inhibitors of pcsk9
|
IL295388A
(en)
|
2020-02-12 |
2022-10-01 |
Curadev Pharma Pvt Ltd |
Sting antagonists are small molecules
|
CA3175324A1
(en)
|
2020-03-18 |
2021-09-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
CR20220548A
(es)
|
2020-05-01 |
2022-12-12 |
Pfizer |
Compuestos de azalactama como inhibidores de hpk1
|
KR20230005893A
(ko)
|
2020-05-04 |
2023-01-10 |
다케다 야쿠힌 고교 가부시키가이샤 |
내강 작용 n-(피페리딘-4-일)벤즈아미드 유도체
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
CN115551860A
(zh)
|
2020-05-20 |
2022-12-30 |
北京泰德制药股份有限公司 |
作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
|
CA3183248A1
(en)
|
2020-06-24 |
2021-12-30 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
BR112023000654A2
(pt)
|
2020-07-13 |
2023-04-25 |
Beijing Tide Pharmaceutical Co Ltd |
Composto de pirazolopirimidina usado como inibidor de atr quinase
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
WO2022042676A1
(en)
|
2020-08-27 |
2022-03-03 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
EP4251634A1
(de)
|
2020-11-25 |
2023-10-04 |
Sage Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von zns-erkrankungen
|
BR112023017731A2
(pt)
|
2021-03-18 |
2023-10-03 |
Pfizer |
Moduladores de sting (estimulador de genes de interferon)
|
WO2022207673A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
CA3214567A1
(en)
|
2021-04-07 |
2022-10-13 |
Martin AMBLER |
2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
|
US11649299B2
(en)
|
2021-06-10 |
2023-05-16 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Purification of sulfobutylated cyclodextrins with specific ion exchange resins
|
KR20240027048A
(ko)
|
2021-06-26 |
2024-02-29 |
어레이 바이오파마 인크. |
Her2 돌연변이 억제제
|
KR20240037975A
(ko)
|
2021-07-28 |
2024-03-22 |
세이지 테라퓨틱스, 인크. |
신경활성 스테로이드의 결정질 형태
|
TW202321232A
(zh)
|
2021-08-11 |
2023-06-01 |
印度商裘拉德製藥私人有限公司 |
小分子sting拮抗劑
|
IL310679A
(en)
|
2021-08-11 |
2024-04-01 |
Curadev Pharma Pvt Ltd |
Urea history of small molecules as STING antagonists
|
WO2023049295A1
(en)
|
2021-09-22 |
2023-03-30 |
Sage Therapeutics, Inc. |
Deuterated positive nmda-modulating compounds and methods of use thereof
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
WO2023144692A1
(en)
*
|
2022-01-25 |
2023-08-03 |
Leiutis Pharmaceuticals Llp |
Novel naproxen sodium preparations for parenteral
|
WO2023156966A1
(en)
|
2022-02-18 |
2023-08-24 |
Beren Therapeutics P.B.C. |
Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
TW202345838A
(zh)
|
2022-04-07 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
稠合噠嗪衍生物
|
WO2023205165A1
(en)
*
|
2022-04-22 |
2023-10-26 |
Brii Biosciences Offshore Limited |
A polymyxin composition and methods for producing the same
|
EP4332087A1
(de)
|
2022-04-29 |
2024-03-06 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipidnanopartikel
|
CN116969851A
(zh)
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
WO2024026337A1
(en)
|
2022-07-27 |
2024-02-01 |
Sage Therapeutics, Inc. |
Crystalline forms of a neuroactive steroid
|
US20240109915A1
(en)
|
2022-07-29 |
2024-04-04 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024059608A1
(en)
|
2022-09-15 |
2024-03-21 |
Sage Therapeutics, Inc. |
Deuterated neuroactive steroids
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|